Finally, some data.
Here is where Azer-cel + chemotherapy compares to some of the other Allogeneic CAR-T therapies in combination with chemotherapy.
In comparison to peer allogeneic CAR T therapies, Azer-cel appears to be underperrforming as well as lagging behind in clinical development. With so many competitors, the risk of clinical and moreso commercial success is very high.
https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00554-0/fulltext
https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.7025
https://www.sciencedirect.com/science/article/pii/S0006497121022990
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32334-5/abstract
https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.2517
https://www.nature.com/articles/s41591-023-02785-8
Finally, some data.Here is where Azer-cel + chemotherapy...
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.6¢ |
Change
0.014(22.6%) |
Mkt cap ! $587.9M | |||
| Open | High | Low | Value | Volume |
| 7.3¢ | 8.1¢ | 7.3¢ | $9.571M | 123.3M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 2182036 | 7.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.7¢ | 934673 | 10 |
View Market Depth
| Last trade - 11.55am 02/09/2024 (20 minute delay) ? |
| IMU (ASX) Chart |